This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
MRTX1133 is a non-covalent, reversible, long-acting inhibitor of KRASG12D entering clinical development for cancer as an oral agent. Mutant KRAS…
molecule
7 months ago ●
2 mins read
Readers have been asking for more molecules, so this month, we’re starting a new feature that will highlight a few…
Article
1 year ago ●
6 mins read
Deucravacitinib (Sotyktu) is a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor, FDA-approved in September 2022 for moderate-to-severe plaque psoriasis.…
molecule
7 months ago ●
4 mins read
with Julien Lefranc We asked one of our reviewers, Julien Lefranc, about what inspires and excites him about drug discovery.…
Article
1 year ago ●
4 mins read
The first approved non-covalent BTK inhibitor. As the nexus of the B cell receptor (BCR) signaling pathway, BTK has been…
molecule
7 months ago ●
8 mins read
A fat-tissue-targeting clinical candidate, a first-in-class Ph. III molecule that inhibits its target by covalently modifying the target’s substrate, and…
Article
1 year ago ●
1 min read
Load More
